Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
<h4>Background</h4>The aim of this study was to assess the role of skin rash in predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the prognosis of patients with non-small cell lung cancer (NSCLC).<h4>Method</h4>We systemati...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0055128&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319539744964608 |
|---|---|
| author | Hong-bing Liu Ying Wu Tang-feng Lv Yan-wen Yao Yong-ying Xiao Dong-mei Yuan Yong Song |
| author_facet | Hong-bing Liu Ying Wu Tang-feng Lv Yan-wen Yao Yong-ying Xiao Dong-mei Yuan Yong Song |
| author_sort | Hong-bing Liu |
| collection | DOAJ |
| description | <h4>Background</h4>The aim of this study was to assess the role of skin rash in predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the prognosis of patients with non-small cell lung cancer (NSCLC).<h4>Method</h4>We systematically searched for eligible articles investigating the association between rash and the efficacy of EGFR-TKIs and the prognosis of patients with NSCLC. The summary risk ratio (RR) and hazard ratio (HR) were calculated using meta-analysis.<h4>Results</h4>We identified 33 eligible trials involving 6,798 patients. We used two different standards to group the patients [standard 1: rash vs. no rash, standard 2: rash (≥ stage 2) vs. rash (stage 0, 1)]. For standard 1, the objective response rate (ORR) and disease control rate (DCR) of the rash group were significantly higher than the no rash group [RR = 3.28; 95% CI: 2.41-4.47(corrected RR = 2.225, 95% CI: 1.658-2.986); RR = 1.96, 95% CI: 1.58-2.43]. The same results were observed for standard 2. For standards 1 and 2, the progression-free survival (PFS) (HR = 0.45, 95% CI: 0.37-0.53; HR = 0.57, 95% CI: 0.50-0.65) and overall survival (OS) (HR = 0.40, 95% CI: 0.28-0.52; HR = 0.53, 95% CI: 0.35-0.71) of the rash group were significantly longer than the control group, and the same results were observed in the subgroup analysis.<h4>Conclusions</h4>skin rash after EGFR-TKI treatment may be an efficient clinical marker for predicting the response of patients with NSCLC to EGFR-TKIs. Furthermore, skin rash is also the prognostic factor of patients with NSCLC. Patients with skin rash have a longer PFS and OS. |
| format | Article |
| id | doaj-art-98f5613a8b274eb4a0bafbfcb0dafa00 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-98f5613a8b274eb4a0bafbfcb0dafa002025-08-20T03:50:25ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0181e5512810.1371/journal.pone.0055128Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.Hong-bing LiuYing WuTang-feng LvYan-wen YaoYong-ying XiaoDong-mei YuanYong Song<h4>Background</h4>The aim of this study was to assess the role of skin rash in predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the prognosis of patients with non-small cell lung cancer (NSCLC).<h4>Method</h4>We systematically searched for eligible articles investigating the association between rash and the efficacy of EGFR-TKIs and the prognosis of patients with NSCLC. The summary risk ratio (RR) and hazard ratio (HR) were calculated using meta-analysis.<h4>Results</h4>We identified 33 eligible trials involving 6,798 patients. We used two different standards to group the patients [standard 1: rash vs. no rash, standard 2: rash (≥ stage 2) vs. rash (stage 0, 1)]. For standard 1, the objective response rate (ORR) and disease control rate (DCR) of the rash group were significantly higher than the no rash group [RR = 3.28; 95% CI: 2.41-4.47(corrected RR = 2.225, 95% CI: 1.658-2.986); RR = 1.96, 95% CI: 1.58-2.43]. The same results were observed for standard 2. For standards 1 and 2, the progression-free survival (PFS) (HR = 0.45, 95% CI: 0.37-0.53; HR = 0.57, 95% CI: 0.50-0.65) and overall survival (OS) (HR = 0.40, 95% CI: 0.28-0.52; HR = 0.53, 95% CI: 0.35-0.71) of the rash group were significantly longer than the control group, and the same results were observed in the subgroup analysis.<h4>Conclusions</h4>skin rash after EGFR-TKI treatment may be an efficient clinical marker for predicting the response of patients with NSCLC to EGFR-TKIs. Furthermore, skin rash is also the prognostic factor of patients with NSCLC. Patients with skin rash have a longer PFS and OS.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0055128&type=printable |
| spellingShingle | Hong-bing Liu Ying Wu Tang-feng Lv Yan-wen Yao Yong-ying Xiao Dong-mei Yuan Yong Song Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE |
| title | Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_full | Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_fullStr | Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_full_unstemmed | Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_short | Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. |
| title_sort | skin rash could predict the response to egfr tyrosine kinase inhibitor and the prognosis for patients with non small cell lung cancer a systematic review and meta analysis |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0055128&type=printable |
| work_keys_str_mv | AT hongbingliu skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yingwu skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT tangfenglv skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yanwenyao skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yongyingxiao skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT dongmeiyuan skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis AT yongsong skinrashcouldpredicttheresponsetoegfrtyrosinekinaseinhibitorandtheprognosisforpatientswithnonsmallcelllungcancerasystematicreviewandmetaanalysis |